CY1120656T1 - Αντισωματα ως προς opgl - Google Patents
Αντισωματα ως προς opglInfo
- Publication number
- CY1120656T1 CY1120656T1 CY181100655T CY181100655T CY1120656T1 CY 1120656 T1 CY1120656 T1 CY 1120656T1 CY 181100655 T CY181100655 T CY 181100655T CY 181100655 T CY181100655 T CY 181100655T CY 1120656 T1 CY1120656 T1 CY 1120656T1
- Authority
- CY
- Cyprus
- Prior art keywords
- opgl
- antibodies
- methods
- amount
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
Abstract
Αντισώματα που αλληλεπιδρούν με προσδέτη οστεοπροτεγερίνης (OPGL) περιγράφονται. Μέθοδοι αγωγής οστεοπενικών διαταραχών από χορήγηση μίας φαρμακευτικώς αποτελεσματικής ποσότητας αντισωμάτων ως προς OPGL περιγράφονται. Μέθοδοι ανίχνευσης της ποσότητας του OPGL σε ένα δείγμα χρησιμοποιώντας αντισώματα ως προς OPGL περιγράφονται.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30117201P | 2001-06-26 | 2001-06-26 | |
EP09156995.4A EP2087908B1 (en) | 2001-06-26 | 2002-06-25 | Antibodies to opgl |
EP02749660.3A EP1409016B9 (en) | 2001-06-26 | 2002-06-25 | Antibodies to opgl |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120656T1 true CY1120656T1 (el) | 2019-12-11 |
Family
ID=23162250
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100637T CY1110196T1 (el) | 2001-06-26 | 2010-07-08 | Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl) |
CY2010016C CY2010016I1 (el) | 2001-06-26 | 2010-11-24 | Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl) |
CY181100655T CY1120656T1 (el) | 2001-06-26 | 2018-06-26 | Αντισωματα ως προς opgl |
CY181100747T CY1120658T1 (el) | 2001-06-26 | 2018-07-17 | Αντισωματα ως προς opgl |
CY20191100079T CY1121151T1 (el) | 2001-06-26 | 2019-01-21 | Αντισωματα ως προς opgl |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100637T CY1110196T1 (el) | 2001-06-26 | 2010-07-08 | Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl) |
CY2010016C CY2010016I1 (el) | 2001-06-26 | 2010-11-24 | Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl) |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181100747T CY1120658T1 (el) | 2001-06-26 | 2018-07-17 | Αντισωματα ως προς opgl |
CY20191100079T CY1121151T1 (el) | 2001-06-26 | 2019-01-21 | Αντισωματα ως προς opgl |
Country Status (33)
Country | Link |
---|---|
US (8) | US7364736B2 (el) |
EP (5) | EP1409016B9 (el) |
JP (13) | JP4212470B2 (el) |
KR (2) | KR20040023630A (el) |
CN (2) | CN1547486A (el) |
AR (1) | AR034637A1 (el) |
AT (1) | ATE464068T1 (el) |
AU (2) | AU2002320157C1 (el) |
BR (1) | BRPI0210579B8 (el) |
CA (1) | CA2451955C (el) |
CY (5) | CY1110196T1 (el) |
DE (2) | DE60235989D1 (el) |
DK (4) | DK1409016T4 (el) |
EA (1) | EA021242B9 (el) |
ES (5) | ES2675735T3 (el) |
FR (1) | FR10C0050I2 (el) |
HK (1) | HK1187932A1 (el) |
IL (3) | IL159512A0 (el) |
LU (1) | LU91757I2 (el) |
ME (2) | ME00232B (el) |
MX (1) | MXPA04000134A (el) |
MY (1) | MY143582A (el) |
NO (5) | NO345566B1 (el) |
NZ (4) | NZ530765A (el) |
PL (1) | PL222211B1 (el) |
PT (4) | PT2087908T (el) |
RS (1) | RS54274B1 (el) |
SG (3) | SG173211A1 (el) |
TR (3) | TR201809008T4 (el) |
TW (2) | TWI276443B (el) |
WO (1) | WO2003002713A2 (el) |
YU (1) | YU103003A (el) |
ZA (1) | ZA200400521B (el) |
Families Citing this family (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
CA2274987C (en) | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
HU229841B1 (en) * | 1997-04-15 | 2014-09-29 | Daiichi Sankyo Co Ltd | Antibodies against obm |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
CZ302262B6 (cs) | 1997-04-16 | 2011-01-19 | Amgen Inc. | Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající |
AU762574B2 (en) | 1998-05-14 | 2003-06-26 | Immunex Corporation | Method of inhibiting osteoclast activity |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
AU2001293030B2 (en) | 2000-09-22 | 2007-07-19 | Immunex Corporation | Screening assays for agonists or antagonists of receptor activat or of NF-kB |
UY27087A1 (es) | 2001-01-05 | 2002-06-20 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
PT2087908T (pt) * | 2001-06-26 | 2018-07-16 | Amgen Inc | Anticorpos contra opgl |
CA2481074A1 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
ES2558303T3 (es) | 2002-09-11 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Método de purificación de proteínas |
ATE458006T1 (de) * | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
BR0318454A (pt) | 2003-08-08 | 2006-09-12 | Abgenix Inc | anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos |
US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
SI1689777T1 (sl) * | 2003-11-05 | 2007-08-31 | Ares Trading Sa | Postopek za äśiĺ äśenje il-18 vezavnega proteina |
TWI359026B (en) * | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
EP2336177A1 (en) | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
US20060115901A1 (en) * | 2004-10-22 | 2006-06-01 | Bahram Valamehr | Method and media for single cell serum-free culture of CHO cells |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
MX2007012499A (es) * | 2005-04-11 | 2007-12-06 | Medarex Inc | Purificacion de proteinas. |
AU2015242973C1 (en) * | 2005-06-14 | 2018-07-05 | Amgen Inc. | Self-buffering protein formulations |
JP2008543839A (ja) * | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
AU2006275475A1 (en) * | 2005-07-29 | 2007-02-08 | Amgen Inc. | Formulations that inhibit protein aggregation |
AR056806A1 (es) * | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
DK1994155T4 (da) | 2006-02-13 | 2022-07-25 | Daiichi Sankyo Co Ltd | Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
JP4881946B2 (ja) * | 2006-04-28 | 2012-02-22 | 共立製薬株式会社 | 動物由来蛋白なしで培養可能な猫の細胞、これを用いたウイルスの生産方法、及びワクチンの生産方法 |
WO2008025748A1 (en) | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-containing proteins |
KR20090113340A (ko) * | 2007-03-22 | 2009-10-29 | 임클론 엘엘씨 | 안정한 항체 제제 |
KR101264473B1 (ko) | 2007-05-24 | 2013-05-29 | 아블린쓰 엔.브이. | Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드 |
EP2188313B1 (en) | 2007-08-21 | 2017-11-01 | Amgen, Inc. | Human c-fms antigen binding proteins |
AU2008298904B2 (en) | 2007-09-14 | 2014-10-16 | Amgen Inc. | Homogeneous antibody populations |
AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
ES2540733T3 (es) | 2007-10-11 | 2015-07-13 | Daiichi Sankyo Company, Limited | Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos |
US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
CN102317440B (zh) | 2008-01-09 | 2014-12-03 | 塞尔卡有限公司 | 改进的培养基添加剂及其应用方法 |
CN103720587A (zh) * | 2008-02-07 | 2014-04-16 | 安姆根有限公司 | 稳定化的蛋白组合物 |
AR073072A1 (es) * | 2008-08-19 | 2010-10-13 | Regeneron Pharma | Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano |
CA2753287A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
US20110305693A1 (en) * | 2009-02-24 | 2011-12-15 | Glaxo Group Limited | Anitigen-binding constructs |
WO2010097394A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Multivalent and/or multispecific rankl-binding constructs |
BRPI1006134A2 (pt) | 2009-04-09 | 2016-02-23 | Daiichi Sankyo Co Ltd | anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada. |
AU2010310457B2 (en) | 2009-10-23 | 2015-07-02 | Amgen Inc. | Vial adapter and system |
WO2011094027A1 (en) | 2010-02-01 | 2011-08-04 | Hlavka Edwin J | Bacteriotherapy for clostridium difficile colitis |
CN103025369B (zh) | 2010-06-07 | 2016-07-06 | 安姆根有限公司 | 药物递送装置 |
JP5699030B2 (ja) * | 2010-07-05 | 2015-04-08 | Axis株式会社 | エタネルセプトを含む線維筋痛症の治療剤 |
TW201219568A (en) | 2010-10-05 | 2012-05-16 | Daiichi Sankyo Co Ltd | Antibody targeting osteoclast-related protein Siglec-15 |
JP6159254B2 (ja) | 2010-10-06 | 2017-07-12 | フンダシオ インスティトゥト デ レセルカ ビオメディカ(イエレベ バルセロナ) | 乳がん転移の診断、予後診断、および処置のための方法 |
MX341790B (es) | 2011-03-31 | 2016-09-02 | Amgen Inc | Adaptador de viales y sistema. |
EP2699293B8 (en) | 2011-04-20 | 2022-07-20 | Amgen Inc. | Autoinjector apparatus |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9505840B2 (en) | 2011-05-27 | 2016-11-29 | Ablynx N.V. | Inhibition of bone resorption with RANKL binding peptides |
SI3045187T1 (sl) | 2011-10-14 | 2019-06-28 | Amgen Inc. | Injektor in postopek sestave |
AU2012328739B2 (en) | 2011-10-25 | 2017-11-30 | Prothena Biosciences Limited | Antibody formulations and methods |
US9353153B2 (en) | 2012-02-09 | 2016-05-31 | Riken | Cyclic RNA and protein production method |
US9464133B2 (en) | 2012-03-30 | 2016-10-11 | Daiichi Sankyo Company, Limited | CDR-modified anti-Siglec-15 antibody |
EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
WO2013181575A2 (en) * | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
CN104603288B (zh) | 2012-06-06 | 2018-12-14 | 生物医学研究机构基金会 | 用于肺癌转移的诊断、预后和治疗的方法 |
KR20150036274A (ko) | 2012-07-19 | 2015-04-07 | 알레시아 바이오쎄라퓨틱스 인코포레이티드 | 항-siglec-15 항체 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014035475A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
CA2884182C (en) | 2012-09-07 | 2022-06-14 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US10114022B2 (en) | 2012-10-12 | 2018-10-30 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
SI3081249T1 (sl) | 2012-11-21 | 2021-03-31 | Amgen Inc. | Naprava za dajanje zdravila |
PL2948553T3 (pl) | 2013-01-25 | 2020-11-16 | Baylor College Of Medicine | Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
EP2968775B1 (en) | 2013-03-15 | 2019-12-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
WO2014144096A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
EP2855533A4 (en) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | METHODS RELATING TO CTLA4-FC FUSION PROTEINS |
CA2906394A1 (en) | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
LT2976117T (lt) | 2013-03-22 | 2021-02-25 | Amgen Inc. | Purkštuvas ir surinkimo būdas |
EP2996772B1 (en) | 2013-05-13 | 2018-12-19 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
US9481901B2 (en) | 2013-05-30 | 2016-11-01 | Amgen Inc. | Methods for increasing mannose content of recombinant proteins |
US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
DK3003330T3 (en) | 2013-06-05 | 2018-08-20 | Rebiotix Inc | Microbiota Recovery Treatment (MRI), compositions and methods of preparation |
US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
WO2015018421A1 (en) | 2013-08-07 | 2015-02-12 | Rigshospitalet Copenhagen University Hospital | Antibodies, compounds and derivatives thereof for use in the treatment of male infertility |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
WO2015047994A2 (en) * | 2013-09-24 | 2015-04-02 | The Board Of Regentsl Of The University Of Texas System | A novel hormone that promotes bone resorption and uses thereof |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
EP3524698A1 (en) | 2013-10-09 | 2019-08-14 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the prognosis and treatment of cancer metastasis |
EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
BR112016008946B1 (pt) | 2013-10-24 | 2022-12-27 | Amgen Inc | Injetores e método para montar os injetor |
EP3501575B1 (en) | 2013-10-24 | 2021-12-01 | Amgen Inc. | Drug delivery system with temperature-sensitive-control |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
CN106488932B (zh) * | 2013-12-20 | 2020-07-14 | 财团法人生物技术开发中心 | α-烯醇化酶特异性抗体及其在癌症治疗中的使用方法 |
CN103965357B (zh) * | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
PT3116891T (pt) | 2014-03-10 | 2020-05-18 | Richter Gedeon Nyrt | Purificação de imunoglobulina utilizando passos de pré-limpeza |
SG10201811702TA (en) | 2014-05-07 | 2019-01-30 | Amgen Inc | Autoinjector with shock reducing elements |
SG10201806528QA (en) | 2014-06-03 | 2018-08-30 | Amgen Inc | Controllable drug delivery system and method of use |
EP3521440B1 (en) * | 2014-06-04 | 2022-02-09 | Amgen Inc. | Methods for harvesting mammalian cell cultures |
US10695506B2 (en) | 2014-10-14 | 2020-06-30 | Amgen Inc. | Drug injection device with visual and audio indicators |
AU2015358868A1 (en) | 2014-12-11 | 2017-06-01 | Inbiomotion S.L. | Binding members for human C-Maf |
EP3233163B1 (en) | 2014-12-19 | 2021-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
EP3689394A1 (en) | 2014-12-19 | 2020-08-05 | Amgen Inc. | Drug delivery device with live button or user interface field |
CA3069716C (en) | 2015-02-17 | 2021-11-09 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
US10745461B2 (en) | 2015-02-25 | 2020-08-18 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis |
US10328123B2 (en) | 2015-02-25 | 2019-06-25 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis |
US10111928B1 (en) * | 2015-02-25 | 2018-10-30 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for osteogenesis imperfecta |
JP2018512184A (ja) | 2015-02-27 | 2018-05-17 | アムジエン・インコーポレーテツド | 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置 |
EP4039253A1 (en) | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Methods of treating cancer |
US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10226431B2 (en) | 2015-06-09 | 2019-03-12 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
HU231463B1 (hu) | 2015-08-04 | 2024-01-28 | Richter Gedeon Nyrt. | Módszer rekombináns proteinek galaktóz tartalmának növelésére |
HRP20231544T1 (hr) | 2015-08-13 | 2024-03-15 | Amgen Inc. | Nabijena dubinska filtracija proteina koji vežu antigene |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
MX2018010851A (es) | 2016-03-08 | 2019-02-07 | Janssen Biotech Inc | Anticuerpos de gitr, métodos, y usos. |
US11200298B2 (en) | 2016-03-15 | 2021-12-14 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
MX2018013616A (es) | 2016-05-13 | 2019-02-21 | Amgen Inc | Montaje de cubierta protectora de vial. |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
LT3458610T (lt) | 2016-05-25 | 2021-08-10 | Inbiomotion S.L. | Krūties vėžio terapinis gydymas, remiantis c-maf būkle |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
CN114917185B (zh) | 2016-10-21 | 2023-11-14 | 美国安进公司 | 药物配制品及其制备方法 |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
US10385008B2 (en) | 2017-01-05 | 2019-08-20 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD1901-2HCL |
MX2019008432A (es) | 2017-01-17 | 2019-11-18 | Amgen Inc | Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje. |
MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
CA3052204A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
WO2018164829A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
MX2019010671A (es) | 2017-03-09 | 2019-10-21 | Amgen Inc | Mecanismo de insercion para dispositivo de administracion de farmacos. |
KR102651078B1 (ko) | 2017-03-28 | 2024-03-22 | 암겐 인코포레이티드 | 플런저 로드 및 주사기 조립 시스템 및 방법 |
JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
BR112019022873A8 (pt) | 2017-05-02 | 2023-04-11 | Merck Sharp & Dohme | Formulação, e, vaso ou dispositivo de injeção. |
CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
WO2018226515A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
JP7475860B2 (ja) | 2017-06-23 | 2024-04-30 | アムジエン・インコーポレーテツド | スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス |
ES2972207T3 (es) | 2017-07-14 | 2024-06-11 | Amgen Inc | Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY |
JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
MA49677A (fr) | 2017-07-25 | 2021-04-21 | Amgen Inc | Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé |
US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD |
MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
US11826480B2 (en) | 2017-11-03 | 2023-11-28 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
EP3706830A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Drug delivery device with placement and flow sensing |
WO2019094138A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
WO2019099324A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
CN111263651B (zh) | 2017-11-16 | 2022-06-17 | 安进公司 | 具有停顿和终点检测的自动注射器 |
CN111565725A (zh) | 2017-11-22 | 2020-08-21 | 生物运动有限公司 | 基于c-maf状态的乳腺癌的治疗性处理 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
AU2019297421A1 (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD 1901-2HCL |
CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
US20210369982A1 (en) | 2018-07-24 | 2021-12-02 | Amgen Inc. | Delivery devices for administering drugs |
CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
CA3106452A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
IL281469B1 (en) | 2018-09-28 | 2024-04-01 | Amgen Inc | Assembling a memory alloy ejector activation assembly for a drug delivery device |
WO2020072577A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
EP3860686A1 (en) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Drug delivery device having dose indicator |
EP3866889A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Platform assembly process for drug delivery device |
WO2020081479A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Drug delivery device having damping mechanism |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
EP3873566A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
HUP1800376A2 (hu) | 2018-11-07 | 2020-05-28 | Richter Gedeon Nyrt | Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer |
HU231498B1 (hu) | 2019-04-04 | 2024-05-28 | Richter Gedeon Nyrt | Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelõzõ flokkulálás alkalmazásával |
US20220160972A1 (en) | 2019-04-24 | 2022-05-26 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
WO2020222668A1 (en) | 2019-04-30 | 2020-11-05 | Instituto de Medicina Molecular João Lobo Antunes | Rank pathway inhibitors in combination with cdk inhibitors |
CA3148261A1 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
WO2021149012A1 (en) | 2020-01-24 | 2021-07-29 | Radius Health, Inc. | Methods of stimulating bone growth with abalopartide and denosumab |
CN113621060B (zh) * | 2020-05-07 | 2023-07-04 | 浙江瑞硕生物技术有限公司 | 一种opg抗体对及其应用 |
WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
WO2024064878A1 (en) | 2022-09-23 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of melanoma |
WO2024104409A1 (zh) * | 2022-11-16 | 2024-05-23 | 苏州盛迪亚生物医药有限公司 | 一种含抗rankl-ngf双特异性抗体的药物组合物 |
Family Cites Families (290)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4755465A (en) * | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
US4710457A (en) * | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
US5900400A (en) | 1984-12-06 | 1999-05-04 | Amgen Inc. | Serine protease inhibitor analogs |
US4760130A (en) | 1984-12-06 | 1988-07-26 | Synergen Biologicals, Inc. | Serine protease inhibitors and methods for isolation of same |
JPS6291197A (ja) | 1985-10-17 | 1987-04-25 | Dainippon Pharmaceut Co Ltd | 抗ヒトインタ−ロイキン1抗体,その製法及びその使用法 |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5359032A (en) | 1987-08-26 | 1994-10-25 | Biogen Inc. | Interkeukin-1 inhibitor |
IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
US5512544A (en) | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5319071A (en) | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
US5811261A (en) | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
DE68925935T2 (de) | 1988-10-01 | 1996-08-14 | Otsuka Pharma Co Ltd | Antikörper gegen Interleukin-1-beta |
FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
IL107267A (en) | 1993-10-12 | 2009-07-20 | Yeda Res & Dev | Ligand to a member of the tnf/ngf receptor family |
AU636608B2 (en) | 1989-05-18 | 1993-05-06 | Yeda Research And Development Co. Ltd. | Tumor necrosis factor binding protein II, it's purification and antibodies thereto |
WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
US5627262A (en) | 1989-07-05 | 1997-05-06 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
JPH03127800A (ja) | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
ES2103305T3 (es) | 1989-11-29 | 1997-09-16 | Amgen Boulder Inc | Produccion de inhibidor de interleuquina-1 humana recombinada. |
CA2032191C (en) | 1989-12-13 | 1999-05-18 | David Wallach | Expression of the recombinant tumor necrosis factor binding protein i (tbp-i) |
US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
AU649245B2 (en) | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
WO1991017184A1 (en) | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
ATE178094T1 (de) | 1990-05-01 | 1999-04-15 | Chiron Corp | Interleukin-i antagonist und seine verwendung |
US5872095A (en) | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
GB2246569A (en) | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
ES2251009T3 (es) | 1990-06-28 | 2006-04-16 | Sanofi-Aventis Deutschland Gmbh | Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso. |
WO1992001002A1 (fr) | 1990-07-11 | 1992-01-23 | Teijin Limited | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation |
AU8292091A (en) | 1990-08-03 | 1992-03-02 | Smithkline Beecham Corporation | Tnf inhibitors |
US5824549A (en) | 1990-10-09 | 1998-10-20 | Chiron Corporation | Transformed human T cell |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5858355A (en) | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
NZ314630A (en) | 1991-01-17 | 2000-11-24 | Harvard College | Use of trans-splicing ribozymes for genetic modification and cell ablation in a host cell |
JP2864434B2 (ja) | 1991-01-18 | 1999-03-03 | サイナーゲン,インコーポレーテッド | 腫瘍壊死因子媒介疾患の治療方法 |
AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
CA2121473C (en) | 1991-10-15 | 2001-05-01 | Michael Mullarkey | Methods and compositions for treating allergic reactions |
US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
ES2038546B1 (es) | 1991-11-08 | 1994-02-16 | Andromaco Lab | Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral. |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
DE69332634T2 (de) | 1992-03-04 | 2003-05-08 | Cell Therapeutics Inc | Enantiomere hydroxylierte xanthinverbindungen |
CA2133326C (en) | 1992-03-30 | 2005-03-01 | Craig A. Smith | Fusion proteins comprising tumor necrosis factor receptor |
AU672606B2 (en) | 1992-04-30 | 1996-10-10 | Amgen, Inc. | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
JPH05312248A (ja) | 1992-05-08 | 1993-11-22 | Nissan Motor Co Ltd | シフトレバー装置 |
DE4219626A1 (de) | 1992-06-16 | 1993-12-23 | Wehling Peter Priv Doz Dr Med | Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen |
JPH0630788A (ja) | 1992-07-16 | 1994-02-08 | Otsuka Pharmaceut Co Ltd | ヒトインターロイキン−1に対する組換え抗体 |
US5545716A (en) | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
NZ256328A (en) | 1992-09-17 | 1997-06-24 | Amgen Boulder Inc | Pharmaceutical compositions of interleukin-1 inhibitor and non-ionic surfactant or viscosity enhancer |
JPH06111399A (ja) | 1992-09-30 | 1994-04-22 | Sony Corp | 光磁気記録媒体及びその製造方法 |
US5646154A (en) | 1992-10-07 | 1997-07-08 | Sumitomo Pharmaceuticals Co., Ltd. | Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor |
WO1994009818A1 (en) * | 1992-10-30 | 1994-05-11 | The Regents Of The University Of California | Method for stimulating production of variable region gene family restricted antibodies through b-cell superantigen vaccination |
US5866576A (en) | 1992-12-16 | 1999-02-02 | Cell Therapeutics, Inc. | Epoxide-containing compounds |
EP0607776B1 (de) | 1993-01-08 | 1998-12-09 | Hoechst Aktiengesellschaft | Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha |
DE122009000074I1 (de) | 1993-03-05 | 2011-12-01 | Bayer Healthcare Ag | Humane monoklonale anti-TNF alpha Antikorper. |
EP0701563A4 (en) | 1993-03-08 | 1997-07-02 | Univ Pittsburgh | GENE TRANSFER FOR THE TREATMENT OF CONNECTIVE TISSUES IN A HOST MAMMAL |
ATE226828T1 (de) | 1993-03-19 | 2002-11-15 | Vacsyn Sa | Zusammensetzungen für die anwendung in menschlicher therapie, charakterisiert durch die assoziation eines muramylpeptids mit einem cytokin |
US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US5843905A (en) | 1993-06-04 | 1998-12-01 | Vertex Pharmaceuticals, Incorporated | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors |
FR2706772A1 (en) | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
DE69430747T2 (de) | 1993-07-28 | 2003-03-06 | Aventis Pharma Ltd | Verbindungen als pde iv und tnf inhibitoren |
PT731791E (pt) | 1993-11-29 | 2000-11-30 | Merrell Pharma Inc | Novos derivados de benzeno-sulfonil-imina como inibidores da accao da il-1. |
CA2138305A1 (en) | 1993-12-28 | 1995-06-29 | Naohito Ohashi | Tumor necrosis factor production inhibitors |
GB9401460D0 (en) | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
JPH09511496A (ja) | 1994-02-18 | 1997-11-18 | セル・セラピューティックス・インコーポレーテッド | 細胞内メッセンジャー |
WO1995024398A1 (en) | 1994-03-09 | 1995-09-14 | Pfizer Inc. | Isoxazoline compounds as inhibitors of tnf release |
US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
US5817822A (en) | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
IL114417A0 (en) | 1994-07-07 | 1995-10-31 | Res Dev Foundation | Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use |
US5877180A (en) | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
DE69519454T2 (de) | 1994-07-14 | 2001-05-03 | Hayashibara Biochem Lab | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen |
US5641747A (en) | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
US5633227A (en) | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
AU695796B2 (en) | 1994-10-05 | 1998-08-20 | Darwin Discovery Limited | Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases |
US5852173A (en) | 1994-10-19 | 1998-12-22 | Genetics Institute, Inc. | TNF receptor death ligand proteins and inhibitors of ligand binding |
TW464656B (en) | 1994-11-15 | 2001-11-21 | Hayashibara Biochem Lab | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease |
ZA9510826B (en) | 1994-12-23 | 1996-06-20 | Smithkline Beecham Corp | 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds |
EP0796096A4 (en) | 1994-12-23 | 1998-04-29 | Smithkline Beecham Corp | 4,4- (DISUBSTITUTED) CYCLOHEXAN-1-CARBOXYLATE MONOMERS AND RELATED COMPOUNDS |
US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5886010A (en) | 1995-01-09 | 1999-03-23 | Otsuka Pharmaceutical Company, Limited | TNF-αinhibitor |
PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
CA2210499A1 (en) | 1995-02-23 | 1996-08-29 | Novartis Nutrition Ag | Amino acid compositions and use thereof in a clinical nutrition |
WO1996028546A1 (en) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
EP0737471A3 (fr) | 1995-04-10 | 2000-12-06 | L'oreal | Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue |
EP0821671B1 (en) | 1995-04-20 | 2000-12-27 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
CA2217850A1 (en) | 1995-05-10 | 1996-11-14 | Chirotech Technology Limited | Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use |
AR004471A1 (es) | 1995-05-31 | 1998-12-16 | Smithkline Beecham Corp | Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen |
US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US5830742A (en) | 1995-06-08 | 1998-11-03 | Immunex Corporation | TNF-α converting enzyme |
DE69635480T2 (de) | 1995-06-29 | 2006-08-17 | Immunex Corp., Thousand Oaks | Apoptosis induzierendes cytokin |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
ZA966663B (en) | 1995-08-17 | 1998-02-06 | Genentech Inc | Traf Inhibitors. |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
EP0859779A4 (en) | 1995-08-31 | 2000-04-12 | Smithkline Beecham Corp | INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS |
IL115245A (en) | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
WO1997012244A1 (en) | 1995-09-27 | 1997-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining t-cell profiles of immunocompromised subjects |
EP0859784B1 (en) | 1995-10-05 | 2002-12-18 | Darwin Discovery Limited | Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation |
DE19540475A1 (de) | 1995-10-20 | 1997-04-24 | Schering Ag | Chirale Methylphenyloxazolidinone |
CA2237524A1 (en) | 1995-11-14 | 1997-05-22 | Du Pont Pharmaceuticals Company | Novel macrocyclic compounds as metalloprotease inhibitors |
US6281352B1 (en) | 1995-11-14 | 2001-08-28 | Dupont Pharmaceuticals Company | Macrocyclic compounds as metalloprotease inhibitors |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CO4750805A1 (es) * | 1995-12-13 | 1999-03-31 | Sumitomo Chemical Co | Compuesto para champu |
US5869315A (en) | 1995-12-18 | 1999-02-09 | Basf Aktiengesellschaft | Modified interleukin-1β converting enzyme with increased stability |
US5891883A (en) | 1995-12-21 | 1999-04-06 | Smithkline Beecham Corporation | 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds |
US5990119A (en) | 1995-12-21 | 1999-11-23 | Smithkline Beecham Corporation | 1,4,4-(trisubstituted)cyclohexane monomers and related compounds |
US5869677A (en) | 1995-12-21 | 1999-02-09 | Smithkline Beecham Corporation | 3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
CA2238885A1 (en) | 1995-12-29 | 1997-07-10 | Incyte Pharmaceuticals, Inc. | Nucleic acids encoding interferon gamma inducing factor-2 |
US6046048A (en) | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
NZ331163A (en) | 1996-02-09 | 2000-07-28 | Amgen Inc | Composition comprising interleukin-1 inhibitor and hydrogel ester (hyaluronan) for treating inflammatory diseases |
JP3861118B2 (ja) | 1996-02-09 | 2006-12-20 | アボット バイオテクノロジーズ リミテッド | ヒトTNFαに結合するヒト抗体 |
US5994351A (en) | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
US5981220A (en) | 1996-03-27 | 1999-11-09 | Human Genome Sciences, Inc. | Epidermal differentiation factor |
GB9607119D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
GB9607249D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
GB9607120D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
US5710013A (en) | 1996-04-19 | 1998-01-20 | Tularik Inc. | Tumor necrosis factor receptor associated factor 6 (TRAF6) |
GB9609795D0 (en) | 1996-05-10 | 1996-07-17 | Smithkline Beecham Plc | Novel compounds |
AUPO048296A0 (en) | 1996-06-14 | 1996-07-11 | Fujisawa Pharmaceutical Co., Ltd. | New compound and its preparation |
EP1669454A3 (en) | 1996-06-27 | 2009-04-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma |
EP0818439B1 (en) | 1996-07-02 | 1999-10-13 | Nisshin Flour Milling Co., Ltd. | Imide derivatives |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
JPH10130149A (ja) | 1996-07-12 | 1998-05-19 | Sankyo Co Ltd | Tnf産生抑制剤 |
US5853977A (en) | 1996-07-12 | 1998-12-29 | Schering Corporation | Mammalian TNF-α convertases |
US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
GB9616643D0 (en) | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
US5929117A (en) | 1996-08-12 | 1999-07-27 | Celgene Corporation | Immunotherapeutic agents |
US6069132A (en) | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
EP0882714B1 (en) | 1996-09-25 | 2004-03-03 | SS Pharmaceutical Co., Ltd. | Substituted vinylpyridine derivatives and drugs containing the same |
US5962481A (en) | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
GB9621859D0 (en) | 1996-10-21 | 1996-12-11 | Xenova Ltd | Cytokine production inhibitors |
GB9712761D0 (en) | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
JPH10147531A (ja) | 1996-11-19 | 1998-06-02 | Otsuka Pharmaceut Co Ltd | TNF−α産生抑制剤 |
EP0948257A4 (en) | 1996-11-20 | 1999-12-29 | Merck & Co Inc | TRIARYL-SUBSTITUTED IMIDAZOLES, COMPOSITIONS CONTAINING THE SAME AND METHOD FOR THEIR USE |
US5955480A (en) | 1996-11-20 | 1999-09-21 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
US5834435A (en) | 1996-11-27 | 1998-11-10 | Slesarev; Vladimir I. | Inhibition of TNF-α pleiotropic and cytotoxic effects |
KR100942002B1 (ko) | 1996-12-03 | 2010-02-12 | 암젠 프레몬트 인코포레이티드 | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체 |
ATE247974T1 (de) | 1996-12-06 | 2003-09-15 | Amgen Inc | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen |
DE19652227A1 (de) | 1996-12-16 | 1998-06-18 | Bosch Gmbh Robert | Verfahren und Vorrichtung zum Zuordnen einer Fernbedienung zu einer Basisstation |
JPH10231285A (ja) | 1996-12-17 | 1998-09-02 | Ishihara Sangyo Kaisha Ltd | フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物 |
CA2274987C (en) | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
US5952320A (en) | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
ZA9818B (en) | 1997-01-07 | 1998-07-02 | Abbott Lab | C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion |
US6054559A (en) | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
YU33799A (sh) | 1997-01-29 | 2002-03-18 | Pfizer Inc. | Derivati sulfonil karbamida i njihova upotreba u kontroli interleukin-1 aktivnosti |
JP3955352B2 (ja) * | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
WO1998039315A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
WO1998039326A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
DE69828783T2 (de) | 1997-03-04 | 2006-01-12 | Pharmacia Corp. | Hydroxamsäure-sulfonamid-derivate mit amidiertem aromatischen ring |
JP2002513407A (ja) | 1997-03-04 | 2002-05-08 | モンサント カンパニー | N−ヒドロキシ4−スルホニルブタンアミド化合物 |
WO1998039316A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
US6087116A (en) | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
JPH10259140A (ja) | 1997-03-18 | 1998-09-29 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生抑制剤 |
US6054487A (en) | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
PL336464A1 (en) | 1997-03-18 | 2000-06-19 | Basf Ag | Method of and compositions for modulating reactivity in respect to corticosteroids i |
WO1998042325A2 (en) | 1997-03-21 | 1998-10-01 | Cistron Biotechnology, Inc. | INHIBITION OF THE CLEAVAGE OF PRECURSOR IL-1$g(b) |
GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
JP2001517225A (ja) | 1997-03-28 | 2001-10-02 | ゼネカ リミテッド | N−(3−ヒドロキシ−スクシニル)−アミノ酸誘導体調製のためのプロセス |
US6251913B1 (en) | 1997-03-28 | 2001-06-26 | Zeneca Limited | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor |
US6380218B1 (en) | 1997-04-04 | 2002-04-30 | Pfizer Inc | Nicotinamide derivatives |
IL132293A0 (en) | 1997-04-10 | 2001-03-19 | Agennix Inc | Use of lactoferin in the treatment of allergen induced disorders |
HU229841B1 (en) | 1997-04-15 | 2014-09-29 | Daiichi Sankyo Co Ltd | Antibodies against obm |
CZ302262B6 (cs) * | 1997-04-16 | 2011-01-19 | Amgen Inc. | Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
FR2762315B1 (fr) | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha |
KR100568438B1 (ko) | 1997-04-24 | 2006-04-07 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 염증성 질환의 치료에 유용한 치환된 이미다졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
FR2762514B1 (fr) | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Icam−1産生阻害剤 |
JP2002502379A (ja) | 1997-05-22 | 2002-01-22 | ジー.ディー.サール アンド カンパニー | p38キナーゼインヒビターとしての3(5)−ヘテロアリール置換ピラゾール |
US6265535B1 (en) | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
JPH111481A (ja) | 1997-06-10 | 1999-01-06 | Sumitomo Pharmaceut Co Ltd | ピペリジニルフタラジン誘導体 |
KR19990001101A (ko) | 1997-06-12 | 1999-01-15 | 손경식 | 캐테콜 아미노산 유도체, 이의 제조방법 및 그를 함유한 약제 조성물 |
ES2270520T3 (es) | 1997-06-12 | 2007-04-01 | Aventis Pharma Limited | Imidazolil-acetales ciclicos. |
EP1023066A4 (en) | 1997-06-13 | 2001-05-23 | Smithkline Beecham Corp | NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND |
GB9713732D0 (en) | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Substituted triazinic compounds |
GB9713733D0 (en) | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Poly-branched polycarboxamido compounds |
EP0994858A1 (en) | 1997-06-30 | 2000-04-26 | Ortho-McNeil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
US6235787B1 (en) | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
US5843721A (en) | 1997-07-03 | 1998-12-01 | Tularik Inc. | Nucleic acids encoding human NIK protein |
US6277981B1 (en) | 1997-07-03 | 2001-08-21 | Thomas Jefferson University | Method for design and selection of efficacious antisense oligonucleotides |
EP0925289A1 (en) | 1997-07-10 | 1999-06-30 | PHARMACIA & UPJOHN S.p.A. | Matrix metalloproteinase inhibitors |
DE19731521A1 (de) | 1997-07-23 | 1999-01-28 | Byk Gulden Lomberg Chem Fab | Budipin bei der Behandlung entzündlicher Erkrankungen des Nervensystems |
AR016551A1 (es) | 1997-07-30 | 2001-07-25 | Smithkline Beecham Corp | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos |
FR2766822B1 (fr) | 1997-07-30 | 2001-02-23 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
RU2199530C2 (ru) | 1997-07-31 | 2003-02-27 | Селджин Корпорейшн | ЗАМЕЩЕННЫЕ ГИДРОКСАМОВЫЕ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ TNFα |
JP2003524572A (ja) | 1997-08-04 | 2003-08-19 | アムジエン・インコーポレーテツド | ヒドロキサム酸置換縮合複素環メタロプロテイナーゼ阻害剤 |
DE69837268D1 (de) | 1997-08-04 | 2007-04-19 | Millennium Pharm Inc | Neue moleküle aus der familie der tango-77-ähnlichen proteine und ihre verewendungen. |
CN1158281C (zh) | 1997-08-06 | 2004-07-21 | 第一三得利制药株式会社 | 作为iv型磷酸二酯酶抑制剂的1-芳基-1,8-二氮杂萘-4-酮衍生物 |
DK0895988T3 (da) | 1997-08-08 | 2002-09-09 | Pfizer Prod Inc | Arylsulfonylaminohydroxamsyrederivater |
WO1999007679A1 (en) | 1997-08-08 | 1999-02-18 | Chiroscience Limited | Peptidyl compounds having mmp and tnf inhibitory activity |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US5994396A (en) | 1997-08-18 | 1999-11-30 | Centaur Pharmaceuticals, Inc. | Furansulfonic acid derivatives and pharmaceutical compositions containing the same |
WO1999009965A2 (en) | 1997-08-21 | 1999-03-04 | Takeda Chemical Industries, Ltd. | Anti-inflammatory agent |
JP2001521906A (ja) | 1997-11-03 | 2001-11-13 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | 血管新生を阻害し、癌を処置するための方法及び組成物 |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
CN1291980A (zh) | 1998-01-16 | 2001-04-18 | 桑道药品有限公司 | 硫醚呋喃硝酮化合物 |
AU1466399A (en) | 1998-01-20 | 1999-08-02 | Basf Aktiengesellschaft | N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6 -dihydro-1-pyrimidinyl)aceto- xyl)-l-aspartic acid aldehyde as an (in vivo) inhibitor of interleukin-1beta converting enzyme (ice) |
ES2245085T3 (es) | 1998-01-23 | 2005-12-16 | Immunex Corporation | Adn y polipeptidos acpl. |
PT1047781E (pt) | 1998-01-23 | 2004-11-30 | Immunex Corp | Receptores de il-18 |
CA2318743A1 (en) | 1998-01-27 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Novel molecules of the tnf receptor superfamily and uses therefor |
EP1051407A1 (en) | 1998-01-27 | 2000-11-15 | American Cyanamid Company | 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors |
DE69925581T2 (de) | 1998-03-09 | 2006-04-27 | Vertex Pharmaceuticals Inc., Cambridge | 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms |
DE69925268T2 (de) | 1998-03-16 | 2006-03-23 | Cytovia, Inc., San Diego | Dipeptid-Caspase-Inhibitoren und deren Verwendung |
EP2261233A3 (en) | 1998-03-19 | 2011-04-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
IL126024A0 (en) | 1998-03-19 | 1999-05-09 | Yeda Res & Dev | Modulators of the function of receptors of the tnf/ngf receptor family and other proteins |
CN1181817C (zh) | 1998-03-20 | 2004-12-29 | 第一三得利制药株式会社 | 以苯基甲苯醌为有效成分的NF-kB抑制剂 |
KR100589474B1 (ko) | 1998-03-26 | 2006-06-14 | 산텐 세이야꾸 가부시키가이샤 | 신규한 우레아 유도체 |
AU762574B2 (en) | 1998-05-14 | 2003-06-26 | Immunex Corporation | Method of inhibiting osteoclast activity |
CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
EP1110969A4 (en) | 1998-09-01 | 2002-01-09 | Hayashibara Biochem Lab | INTERLEUKIN 18 BINDING PROTEIN |
CN1318105A (zh) * | 1998-09-15 | 2001-10-17 | M&E生物技术公司 | 负调节Osteoprotegerin配体活性的方法 |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000037504A2 (en) * | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
PT2332978E (pt) | 1999-02-03 | 2014-05-23 | Amgen Inc | Novos polipéptidos envolvidos na resposta imunitária |
AU2880400A (en) | 1999-02-12 | 2000-08-29 | Amgen, Inc. | Tnf-related proteins |
AUPQ314799A0 (en) | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
AU2262501A (en) | 1999-12-16 | 2001-06-25 | Amgen, Inc. | Tnfr/opg-like molecules and uses thereof |
WO2001062932A1 (en) † | 2000-02-23 | 2001-08-30 | Amgen Inc. | Antagonistic selective binding agents of osteoprotegerin binding protein |
CA2407956A1 (en) | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides as therapeutic agents |
US7102050B1 (en) | 2000-05-04 | 2006-09-05 | Exxonmobil Chemical Patents Inc. | Multiple riser reactor |
WO2001091793A1 (en) * | 2000-05-26 | 2001-12-06 | Smithkline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
US7405734B2 (en) * | 2000-07-18 | 2008-07-29 | Silicon Graphics, Inc. | Method and system for presenting three-dimensional computer graphics images using multiple graphics processing units |
DE10039710B4 (de) | 2000-08-14 | 2017-06-22 | United Monolithic Semiconductors Gmbh | Verfahren zur Herstellung passiver Bauelemente auf einem Halbleitersubstrat |
AU2001286586A1 (en) * | 2000-08-18 | 2002-03-04 | University Of Massachusetts Medical Center | Trance regulation of chondrocyte differentiation |
EP1458411A4 (en) | 2000-08-21 | 2004-09-22 | Smithkline Beecham Corp | ANTI-RANK LIGAND MONOCLONAL ANTIBODIES SUITABLE FOR THE TREATMENT OF RANK LIGAND RELATED DISORDERS |
UY27087A1 (es) * | 2001-01-05 | 2002-06-20 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
WO2002092016A2 (en) | 2001-05-17 | 2002-11-21 | Immunex Corporation | Therapeutic use of rank antagonists |
JP2005515159A (ja) | 2001-06-06 | 2005-05-26 | イミュネックス・コーポレーション | 癌を治療するためのrankアンタゴニストの使用 |
PT2087908T (pt) | 2001-06-26 | 2018-07-16 | Amgen Inc | Anticorpos contra opgl |
CA2481074A1 (en) † | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2002
- 2002-06-25 PT PT91569954T patent/PT2087908T/pt unknown
- 2002-06-25 NZ NZ530765A patent/NZ530765A/en not_active IP Right Cessation
- 2002-06-25 IL IL15951202A patent/IL159512A0/xx unknown
- 2002-06-25 EP EP02749660.3A patent/EP1409016B9/en not_active Expired - Lifetime
- 2002-06-25 ME MEP-2008-326A patent/ME00232B/me unknown
- 2002-06-25 DK DK02749660.3T patent/DK1409016T4/da active
- 2002-06-25 DE DE60235989T patent/DE60235989D1/de not_active Expired - Lifetime
- 2002-06-25 CN CNA028166809A patent/CN1547486A/zh active Pending
- 2002-06-25 MX MXPA04000134A patent/MXPA04000134A/es active IP Right Grant
- 2002-06-25 WO PCT/US2002/020181 patent/WO2003002713A2/en active Application Filing
- 2002-06-25 DK DK09156995.4T patent/DK2087908T3/en active
- 2002-06-25 RS RS20120347A patent/RS54274B1/en unknown
- 2002-06-25 NO NO20200535A patent/NO345566B1/no not_active IP Right Cessation
- 2002-06-25 PL PL371915A patent/PL222211B1/pl unknown
- 2002-06-25 AU AU2002320157A patent/AU2002320157C1/en active Active
- 2002-06-25 KR KR10-2003-7017009A patent/KR20040023630A/ko active Search and Examination
- 2002-06-25 BR BRPI0210579-9 patent/BRPI0210579B8/pt not_active IP Right Cessation
- 2002-06-25 EP EP10185344.8A patent/EP2295081B1/en not_active Expired - Lifetime
- 2002-06-25 US US10/180,648 patent/US7364736B2/en not_active Expired - Lifetime
- 2002-06-25 ES ES09156995.4T patent/ES2675735T3/es not_active Expired - Lifetime
- 2002-06-25 DE DE122010000047C patent/DE122010000047I1/de active Pending
- 2002-06-25 TR TR2018/09008T patent/TR201809008T4/tr unknown
- 2002-06-25 EP EP10181323.6A patent/EP2270052B8/en not_active Expired - Lifetime
- 2002-06-25 YU YU103003A patent/YU103003A/sh unknown
- 2002-06-25 CN CN201310052370.5A patent/CN103232539B/zh not_active Expired - Lifetime
- 2002-06-25 EP EP09156995.4A patent/EP2087908B1/en not_active Expired - Lifetime
- 2002-06-25 TR TR2018/09678T patent/TR201809678T4/tr unknown
- 2002-06-25 SG SG2005081195A patent/SG173211A1/en unknown
- 2002-06-25 KR KR1020107002067A patent/KR101038585B1/ko active Protection Beyond IP Right Term
- 2002-06-25 EA EA200400063A patent/EA021242B9/ru active Protection Beyond IP Right Term
- 2002-06-25 PT PT101813236T patent/PT2270052T/pt unknown
- 2002-06-25 SG SG2011076551A patent/SG2011076551A/en unknown
- 2002-06-25 PT PT10185344T patent/PT2295081T/pt unknown
- 2002-06-25 NZ NZ616594A patent/NZ616594A/en not_active IP Right Cessation
- 2002-06-25 ES ES02749660T patent/ES2342820T5/es not_active Expired - Lifetime
- 2002-06-25 MY MYPI20022368A patent/MY143582A/en unknown
- 2002-06-25 ES ES10185344T patent/ES2706902T3/es not_active Expired - Lifetime
- 2002-06-25 PT PT02749660T patent/PT1409016E/pt unknown
- 2002-06-25 NZ NZ547695A patent/NZ547695A/en not_active IP Right Cessation
- 2002-06-25 ME MEP-326/08A patent/MEP32608A/xx unknown
- 2002-06-25 ES ES10181323.6T patent/ES2674888T3/es not_active Expired - Lifetime
- 2002-06-25 TR TR2019/00581T patent/TR201900581T4/tr unknown
- 2002-06-25 EP EP18202340.8A patent/EP3492100B1/en not_active Expired - Lifetime
- 2002-06-25 DK DK10181323.6T patent/DK2270052T3/en active
- 2002-06-25 DK DK10185344.8T patent/DK2295081T3/en active
- 2002-06-25 SG SG10201603108QA patent/SG10201603108QA/en unknown
- 2002-06-25 AT AT02749660T patent/ATE464068T1/de active
- 2002-06-25 CA CA2451955A patent/CA2451955C/en not_active Expired - Lifetime
- 2002-06-25 ES ES18202340T patent/ES2907826T3/es not_active Expired - Lifetime
- 2002-06-25 JP JP2003509075A patent/JP4212470B2/ja not_active Expired - Lifetime
- 2002-06-26 TW TW091114055A patent/TWI276443B/zh active
- 2002-06-26 TW TW095103780A patent/TWI326285B/zh not_active IP Right Cessation
- 2002-06-26 AR ARP020102401A patent/AR034637A1/es active IP Right Grant
-
2003
- 2003-12-22 IL IL159512A patent/IL159512A/en active IP Right Grant
-
2004
- 2004-01-23 ZA ZA200400521A patent/ZA200400521B/xx unknown
- 2004-03-10 NO NO20041018A patent/NO343687B1/no not_active IP Right Cessation
-
2005
- 2005-06-25 NZ NZ581637A patent/NZ581637A/en not_active IP Right Cessation
-
2007
- 2007-10-30 US US11/981,664 patent/US8058418B2/en not_active Expired - Lifetime
-
2008
- 2008-07-04 JP JP2008175541A patent/JP4358282B2/ja not_active Expired - Lifetime
- 2008-12-19 AU AU2008261137A patent/AU2008261137C1/en active Active
-
2009
- 2009-07-08 JP JP2009161406A patent/JP4927910B2/ja not_active Expired - Lifetime
-
2010
- 2010-07-08 CY CY20101100637T patent/CY1110196T1/el unknown
- 2010-11-24 CY CY2010016C patent/CY2010016I1/el unknown
- 2010-11-24 LU LU91757C patent/LU91757I2/fr unknown
- 2010-11-25 FR FR10C0050C patent/FR10C0050I2/fr active Active
-
2011
- 2011-11-14 US US13/296,201 patent/US8409578B2/en not_active Expired - Lifetime
-
2012
- 2012-01-17 JP JP2012006740A patent/JP5065529B2/ja not_active Expired - Lifetime
- 2012-03-23 JP JP2012066632A patent/JP2012153701A/ja not_active Withdrawn
- 2012-07-02 JP JP2012148656A patent/JP5576903B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-14 US US13/831,099 patent/US20140134157A1/en not_active Abandoned
-
2014
- 2014-02-05 HK HK14101098.3A patent/HK1187932A1/xx not_active IP Right Cessation
- 2014-10-19 IL IL235116A patent/IL235116A0/en unknown
- 2014-10-28 JP JP2014218929A patent/JP2015057408A/ja active Pending
- 2014-11-27 JP JP2014239576A patent/JP2015078205A/ja active Pending
-
2015
- 2015-02-12 US US14/621,072 patent/US20150266952A1/en not_active Abandoned
-
2016
- 2016-06-07 JP JP2016113389A patent/JP2016216464A/ja active Pending
- 2016-09-02 US US15/256,194 patent/US20170183417A1/en not_active Abandoned
-
2017
- 2017-12-25 JP JP2017247287A patent/JP2018154614A/ja not_active Ceased
-
2018
- 2018-06-26 CY CY181100655T patent/CY1120656T1/el unknown
- 2018-07-17 CY CY181100747T patent/CY1120658T1/el unknown
-
2019
- 2019-01-21 CY CY20191100079T patent/CY1121151T1/el unknown
- 2019-04-04 NO NO20190456A patent/NO344842B1/no not_active IP Right Cessation
- 2019-06-10 JP JP2019107837A patent/JP2019214563A/ja active Pending
- 2019-11-05 NO NO2019039C patent/NO2019039I1/no unknown
- 2019-12-20 NO NO2019048C patent/NO2019048I1/no unknown
- 2019-12-24 JP JP2019232389A patent/JP2020073518A/ja active Pending
-
2020
- 2020-01-09 US US16/738,751 patent/US20200131271A1/en not_active Abandoned
- 2020-06-18 US US16/905,089 patent/US20200354464A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021128771A patent/JP2022000424A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120658T1 (el) | Αντισωματα ως προς opgl | |
CY1117940T1 (el) | Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9) | |
SG155054A1 (en) | Human anti- neutralizing antibodies as selective pathway inhibitors | |
CY1112858T1 (el) | Θεραπευτικο ανθρωπινο αντι-ιl-1r1 μονοκλωνικο αντισωμα | |
DK1247097T3 (da) | Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi | |
PL375041A1 (en) | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors | |
SG164369A1 (en) | Human anti-b7rp1 neutralizing antibodies | |
RS20050975A (en) | Specific binding agents to hepatocyte growth factor | |
CY1105788T1 (el) | Χρηση του taci σαν παραγοντα καταπολεμησης ογκων | |
CL2007001624A1 (es) | Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular. | |
BRPI0413326A (pt) | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel | |
DE50108680D1 (de) | Multispezifisches reagenz zur selektiven stimulierung von zelloberflächenrezeptoren | |
AR024540A1 (es) | Uso de resonancia magnetica nuclear 13 c para detectar la union con moleculas blanco | |
ATE364180T1 (de) | Screeningverfahren mit bnpi und dnpi | |
CY1117637T1 (el) | Ανθρωπινα anti-b7rp1 εξουδετερωτικα αντισωματα | |
ATE323289T1 (de) | Auf tsap6-bindungspartnern beruhendes screeningverfahren |